

June 2024

DIRECT HEALTHCARE PROFESSIONAL COMMUNICATION
VERORAB, powder and solvent for suspension for injection - PLGB 46602/0029
Interim Supply of UK Stock in Standard Export Packaging (Standard Export Packs) to Mitigate Supply Disruption

Dear Healthcare Professional,

There is currently supply disruption of Rabies vaccines in the UK. In order to ensure some continuity of supply of a rabies vaccine to GP surgeries and travel clinics in the UK, Sanofi has obtained approval from the MHRA to supply its product Verorab, PLGB 46602/0029, in Standard Export Packs (Batch X1A931V; Expiry May 2026; 3000 doses), which is expected to be available to the UK market from June/July 2024.

Please note the following:


- This product is considered licensed in the UK.
- Please note the following points regarding the export pack presentation:
 - **The presentation is a single dose containing powder and solvent for suspension for injection in prefilled syringe.**
 - Text in three languages (English, French and Spanish) is included on the Carton and label components of the Standard Export Pack; text in two languages (English and Spanish) on the PIL component of the Standard Export Pack. An image of the Standard Export Pack is provided below.

To access the PIL for the PLGB licence, please refer to [pil.15572.pdf \(medicines.org.uk\)](#) or contact the company contact point (see below).

The MHRA has approved this product under a batch specific variation to the PLGB marketing authorisation.

Please ensure all relevant staff are made aware of the content of this letter and that the information is communicated to the patients.

Verorab Standard Export Packaging



Call for reporting

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to the Sanofi drug safety department on Tel: 0800 0902 314. Alternatively, send via email to UKdrugsafety@sanofi.com.

Company contact point

If you have any questions about this letter or would like more information about VERORAB, please contact Sanofi Medical Information Department on 0800 035 2525 or email uk-medicalinformation@sanofi.com.

Yours faithfully,

To be signed at approval

Tiziano Poletti
Medical Advisor (Vaccines)